We examined here whether this could influence the caspase-3 activation in pancreatic cancer we observed earlier [8-10] and found that LMP occurs shortly following treatment with a variety of structurally diverse sigma-2 receptor ligands, verified by both AO and LysoTracker release from the lysosome. Here, CASP3 is linked to pancreatic neoplasm.